However, the relatively prevalent overexpression of EGFR, c-Kit and VEGF among basal-like and triple-negative breast cancers has maintained hope that current trials underway restricted to these tumor types will maximize the chance of identifying a responsive subgroup of breast cancer and offer more definitive data [104,105,116,117]. The gene discussed is EGFR; the disease is breast cancer.